Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Isr Med Assoc J ; 22(2): 79-82, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-32043323

RESUMO

BACKGROUND: Post-pericardiotomy syndrome (PPS) is a major cause of pericarditis, yet data on the risk of recurrence are limited, and the impact of steroids and colchicine in this context is unknown. OBJECTIVES: To examine the effect of prednisone and colchicine on the rate of recurrence of PPS. METHODS: Medical files of patients diagnosed with PPS were reviewed to extract demographic, echocardiographic, X-ray imaging, and follow-up data. RESULTS: The study comprised 132 patients (57% men), aged 27-86 years. Medical treatment included prednisone in 80 patients, non-steroidal anti-inflammatory agents in 41 patients, colchicine monotherapy in 2 patients, and no anti-inflammatory therapy in 9 patients. Fifty-nine patients were given colchicine for prevention of recurrence. The patients were followed for 5-110 months (median 64 months). Recurrent episodes occurred in 15 patients (11.4%), 10 patients had a single episode, 4 patients had two episodes, and one patient had three episodes. The rate of recurrence was lower in patients receiving colchicine compared to patients who did not (8.5% vs. 13.7%), and in patients not receiving vs. receiving prednisone (7.7% vs. 13.8%) but the differences were non-significant. Twenty-three patients died and there were no recurrence-related deaths. CONCLUSIONS: The rate of recurrence after PPS is low and multiple recurrences are rare. The survival of patients with recurrent PPS is excellent. Prednisone pre-treatment was associated with a numerically higher rate of recurrence and colchicine treatment with a numerically lower rate, but the differences were non-significant.


Assuntos
Anti-Inflamatórios/uso terapêutico , Colchicina/uso terapêutico , Pericardiectomia/efeitos adversos , Síndrome Pós-Pericardiotomia , Prednisona/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Ecocardiografia/métodos , Feminino , Seguimentos , Humanos , Israel , Masculino , Pessoa de Meia-Idade , Pericardiectomia/métodos , Síndrome Pós-Pericardiotomia/diagnóstico , Síndrome Pós-Pericardiotomia/tratamento farmacológico , Síndrome Pós-Pericardiotomia/etiologia , Radiografia Torácica/métodos , Prevenção Secundária/métodos
2.
Cardiology ; : 1-6, 2020 Feb 07.
Artigo em Inglês | MEDLINE | ID: mdl-32036358

RESUMO

INTRODUCTION: Patients undergoing chemotherapy are extremely vulnerable to cardiotoxicity. Early detection of cardiac dysfunction is of vital importance to optimize the management of these patients. OBJECTIVE: The aim of this study was to test the effectiveness of non-invasive hemodynamic whole-body bioimpedance (WBI) technology as a modality to detect heart failure in patients undergoing chemotherapy treatment. METHODS: This retrospective observational trial included 84 patients treated at the cardio-oncology outpatient clinic of the Rabin Medical Center. Clinical assessments were performed including biomarker testing and measurement of hemodynamic and volume status parameters as measured by WBI. RESULTS: We included 84 patients with a median age of 64.8 years, and 40.5% were males. Clinical heart failure was detected in 43% of the whole group. Patients were divided into two groups according to baseline NT-proBNP levels with a cut-off of 900 pg/mL. Left ventricular ejection fraction did not differ between the groups. Those with NT-proBNP >900 pg/mL had lower levels of stroke index, cardiac index, and Granov-Goor index (GGI; 25.9 vs. 34.0, 2.0 vs. 2.3, 8.3 vs. 11.4, respectively, with p < 0.001 for all comparisons). The optimal cut-off value for the GGI to detect NT-proBNP >900 pg/mL was 8.3. The area under the curve of a GGI cut-off <8.3 to detect NT-proBNP >900 pg/mL was 0.81 (positive predictive value 95% and negative predictive value 72%), with a 51% sensitivity and 98% specificity. CONCLUSION: GGI, a parameter measured by WBI, can reliably correlate to biomarker evidence of heart failure in patients after chemotherapy. Its use as a screening tool for cardiotoxicity in patients with ongoing anticancer therapy is promising.

3.
Isr Med Assoc J ; 22(1): 60-63, 2020 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-31927808

RESUMO

BACKGROUND: In this review, the authors re-examine the role of aspirin in the primary prevention of cardiovascular disease. They discuss the history of the use of aspirin in primary prevention, the current guidelines, and the recent evidence surrounding aspirin use as primary prevention in special populations such as those with moderate cardiovascular risk, diabetes mellitus, and the elderly.


Assuntos
Aspirina/uso terapêutico , Doenças Cardiovasculares/prevenção & controle , Fibrinolíticos/uso terapêutico , Aspirina/efeitos adversos , Fibrinolíticos/efeitos adversos , Humanos , Guias de Prática Clínica como Assunto , Prevenção Primária/métodos
4.
Catheter Cardiovasc Interv ; 94(6): 781-782, 2019 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-31737986

RESUMO

This study demonstrated an increasing rate in complete heart block (CHB) and permanent pacemaker (PPM) after trans-catheter aortic valve replacement (TAVR). The development of CHB was associated with increased in-hospital mortality, prolonged length of stay and augmented hospitalization cost. Pre-existing RBBB was the strongest independent risk factor for subsequent development of CHB after TAVR.

5.
Acta Haematol ; 141(4): 209-213, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30943468

RESUMO

A 37-year-old male was admitted with an atypical presentation of central nervous system (CNS) aspergillosis while on ibrutinib therapy for a CNS relapse of mantle cell lymphoma. This case highlights the importance of a high clinical suspicion of opportunistic infections in patients receiving small-molecule kinase inhibitors. This report includes a review of reported cases of Aspergillus infections in patients receiving ibrutinib and the shared features of these cases.


Assuntos
Linfoma de Célula do Manto/tratamento farmacológico , Neuroaspergilose/induzido quimicamente , Pirazóis/efeitos adversos , Pirimidinas/efeitos adversos , Adulto , Humanos , Linfoma de Célula do Manto/diagnóstico por imagem , Linfoma de Célula do Manto/metabolismo , Masculino , Neuroaspergilose/diagnóstico por imagem , Neuroaspergilose/metabolismo , Pirazóis/administração & dosagem , Pirimidinas/administração & dosagem , Recidiva
6.
Acta Haematol ; 140(4): 226-230, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30799402

RESUMO

With the increasing survival of cancer patients and therapeutic advancements, the cardiovascular complications of therapy have become a significant issue. A dedicated, integrated team is important in providing the balance between acquiring a hematological/oncological response and cardiovascular morbidity and mortality. This article aims to shed light on this field - providing some examples of therapies with cardiotoxic potential as well as the cardiologist's approach to patient assessment before, during, and after therapy.


Assuntos
Antineoplásicos/efeitos adversos , Doenças Cardiovasculares/etiologia , Antineoplásicos/uso terapêutico , Humanos , Fatores Imunológicos/efeitos adversos , Fatores Imunológicos/uso terapêutico , Neoplasias/tratamento farmacológico , Neoplasias/radioterapia , Inibidores de Proteínas Quinases/efeitos adversos , Inibidores de Proteínas Quinases/uso terapêutico , Radiação Ionizante
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA